Pandemic Taking Its Toll On The US FDA’s Non-Pandemic Work, Alkermes CEO Says
Executive Summary
Last year was not the greatest performance by the agency outside of COVID-19, Richard Pops tells BIO conference.
You may also be interested in...
Drug Manufacturers Beg US FDA To Inspect Facilities, But Still Find Difficulties
As agency implements testing program for its staff, sponsors are drawing up protocols to ensure inspector safety and forwarding them to FDA, but still can’t trigger an inspection.
US FDA Could Be Facing Bolus Of Pandemic-Related Applications
Acting CDER Director Cavazzoni says it is ‘a very active time’ as many clinical trials for COVID-19-related products are expected to read out soon.
What Pandemic Effect? US FDA’s 2021 Approval Class Is Off To Strong Start With 60+ Novel Candidates
Dermatology, chronic kidney disease and liver disease therapies stand out in a crowd of user fee goals that is actually bigger than at the same point in 2020.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: